India’s first indigenous HPV vaccine gets WHO prequalification 
News

Indian HPV vaccine Cervavac secures WHO clearance for youth aged nine to 26

Clearance enables United Nations bodies to buy the indigenous four-strain vaccine protecting young people against cervical and anal cancer

IANS

New Delhi, Oct 6 (IANS): Cervavac -- India's first indigenously developed human papillomavirus (HPV) vaccine -- has received prequalification from the World Health Organization (WHO) which makes it eligible for procurement by United Nations agencies and expands its potential global reach.

The vaccine -- which was developed by the Serum Institute of India (SII) -- had earlier received approval from India's Drugs Controller General of India (DCGI) for domestic use.

Cervavac is a quadrivalent, gender-neutral vaccine that can be administered to both girls and boys between the ages of nine and 26 years.

It targets four HPV strains -- types 6, 11, 16 and 18. While HPV types 6 and 11 are commonly associated with genital warts, types 16 and 18 are considered high-risk strains linked to several cancers.

In women, the vaccine helps protect against cervical, vulvar, vaginal and anal cancers associated with HPV infection.

On the other hand, in men, it provides protection against HPV-related anal cancer.

According to SII, children aged 9-14 years should receive two doses administered six months apart, while individuals aged 15-26 years require a three-dose schedule within a year.

Commenting on the development, Serum Institute Chief Executive Officer Adar Poonawalla said the WHO prequalification marks an important step in strengthening the global fight against HPV-related diseases and broadening access to preventive vaccination.

The vaccine contains proteins designed to generate an immune response against the four targeted HPV strains and is manufactured using the Hansenula polymorpha expression system.

WHO prequalification is a key benchmark for vaccine quality, safety and efficacy and allows international agencies and global immunisation programmes to procure the product.

Cervavac was developed by SII in partnership with the Department of Biotechnology, Biotechnology Industry Research Assistance Council (BIRAC), WHO's International Agency for Research on Cancer (IARC) and the Gates Foundation.

—

This report was published from a syndicated wire feed. Apart from the headline, the EdexLive Desk has not edited the copy.

KSET 2026 candidates urge KEA to release final results and cutoffs as UGC NET approaches

KSET 2026 Provisional Result Analysis: 343 candidates score 200+ across 12 subjects; Management leads, cutoffs awaited

NEET PG Counselling 2026 Round 2 Seat Allotment Result Expected Today; MCC website says results will be available soon

UGC NET December 2026 subject-wise exam schedule released; check dates for English, Commerce, Management and other subjects

74 new officers inducted into J&K Police, Forest Protection Force at Udhampur academy